-
Atezolizumab, sold
under the
brand name
Tecentriq among others, is a
monoclonal antibody medication used to
treat urothelial carcinoma, non-small cell...
-
Atezolizumab (Tecentriq) is a
fully humanised IgG1 (immunoglobulin 1)
antibody developed by
Roche Genentech. In 2016, the FDA
approved atezolizumab for...
-
combination of
tiragolumab and
atezolizumab reduced the risk of
disease progression or
death by 38%
compared to
atezolizumab monotherapy. In a
subset of...
-
carboplatin plus
etoposide and were
randomized to
receive atezolizumab or placebo.
Atezolizumab was ****ociated with a
significant improvement in overall...
-
treat both
solid tumors and lymphomas. In May 2016, PD-L1
inhibitor atezolizumab was
approved for
treating bladder cancer.
Other modes of
enhancing [adoptive]...
-
combination with
vemurafenib (Zelboraf)
alone or with both
vemurafenib and
atezolizumab (Tecentriq) to
treat melanoma.
Cobimetinib is a MEK inhibitor. Cotellic...
-
chemotherapy plus Bevacizumab,
chemotherapy plus
atezolizumab or
chemotherapy plus
Bevacizumab and
atezolizumab. The
chemotherapy used was Carboplatin, and...
-
inactivate BRCA1 or BRCA2. The
immune checkpoint inhibitor antibody atezolizumab for
those whose tumors express PD-L1. And the
similar immunotherapy pembrolizumab...
-
sometimes effective in
those that do not.
Treatment with pembrolizumab,
atezolizumab, or
combination nivolumab plus
ipilimumab are all
superior to chemotherapy...
- had
undergone surgery then
received atezolizumab, an
immune checkpoint inhibitor. 16 of the
patients on
atezolizumab then
received autogene cevumeran. 1...
